Schizophrenia affects about 1 in 300 people worldwide and typically emerges in late teens to early thirties. Current treatment centers on antipsychotic medications that manage hallucinations and delusions, though many people still struggle with motivation, social withdrawal, and cognitive problems that don't respond well to existing drugs.
What's actually going on in research
Trials are testing drugs that work on different brain receptors than current antipsychotics, including muscarinic receptor modulators and TAAR1 agonists. Researchers are also studying early intervention programs for people experiencing first psychosis, non-medication approaches like cognitive remediation therapy, and drugs targeting negative symptoms like social withdrawal and lack of motivation.
Muscarinic receptor drugs
These medications work differently than dopamine-blocking antipsychotics and may treat symptoms without causing weight gain or movement problems. The FDA approved xanomeline-trospium in 2024, the first new mechanism for schizophrenia in decades.
Negative symptom treatments
New drugs specifically target motivation, social withdrawal, and emotional flatness that leave many people isolated even when hallucinations are controlled. This includes drugs affecting different neurotransmitter systems than traditional antipsychotics.
Early psychosis programs
Studies are testing whether intensive support during first psychosis—combining medication, therapy, and social services—can prevent long-term disability. Some programs aim to intervene even before full psychosis develops.
What to know before you search
Eligibility typically depends on diagnosis confirmation, symptom severity, whether this is a first episode or chronic illness, current medications, and sometimes age at symptom onset.
What types of trials are currently open
- Treatment trials — Testing new antipsychotic medications or drugs with novel mechanisms like muscarinic or TAAR1 targeting. Many compare new drugs against existing antipsychotics.
- Negative symptom trials — Studies focused specifically on motivation, social engagement, and emotional expression rather than hallucinations or delusions.
- Cognitive remediation studies — Testing therapy programs or medications aimed at improving memory, attention, and problem-solving abilities affected by schizophrenia.
- First episode trials — Programs for people experiencing psychosis for the first time, testing whether early comprehensive treatment improves long-term outcomes.
- Side effect studies — Testing whether switching medications or adding other drugs can reduce weight gain, diabetes risk, or movement problems from antipsychotics.
Recently added Schizophrenia trials
FEEL-GOOD: A Multicenter Trial of a Mindfulness-Based Group Therapy in Young Adults With Early Psychosis
FEEL-GOOD is a prospective multi-site single-blinded randomized controlled trial in young inpatients with acute early psychosis. Participants are randomized 1:1 to FEEL-GOOD plus treatment as usual (TAU) or TAU alone. The intervention consists of one individual preparatory session and eight modularized group sessions delivered over four weeks involving four to eight participants at each session and including practice and homework tasks. Outcomes are assessed at baseline, 4 weeks post-intervention, and 6 months follow-up, with the primary outcome being observer-rated total psychopathology as measured with the assessed by the total score of the Positive and Negative Syndrome Scale (PANSS) post-treatment (4 weeks post baseline).
Exploring the Feasibility of Transcranial Ultrasound Stimulation in the Treatment of Schizophrenia
1. The purpose of this study is to evaluate the safety and feasibility of transcranial ultrasound stimulation (TUS) treatment in patients with schizophrenia. Subjects are individuals diagnosed with schizophrenia who will receive non-invasive, low-intensity pulsed ultrasound stimulation targeting the hippocampus and its surrounding regions. Evaluations will be conducted before and after the treatment sessions, including electrocardiograms (ECG), blood biochemistry tests, psychiatric symptom assessments, depression level assessments, and cognitive function assessments. 2. The primary objective is to assess the safety of this intervention in patients with schizophrenia. The secondary objective is to explore whether the current stimulation parameters may lead to improvements in the assessed symptoms. Ultimately, this study aims to support the future application of low-intensity pulsed ultrasound as a potential intervention to alleviate symptoms of schizophrenia and improve patients' quality of daily life.
Find Schizophrenia trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.